PRQR
ProQR Therapeutics BV
1.60$
-1.8%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 98.8% | 97.7% | 94.6% | 95.2% | 98.3% | 97.6% | 81.1% | 91.4% | 90.2% | 87.7% | 91.6% | 88.8% | |
| 97.8% | 94.8% | 90.3% | 90.6% | 95.8% | 95.2% | 76.8% | 89.5% | 55.3% | 86.3% | 89.0% | 82.0% | |
| 97.8% | 94.8% | 90.3% | 90.6% | 95.8% | 95.2% | 76.8% | 89.5% | 55.3% | 86.3% | 89.0% | 82.0% | |
| 0.7% | 1.5% | 2.4% | 0.9% | 1.1% | 1.0% | 0.8% | 0.4% | 33.4% | 0.9% | 1.2% | 4.5% | |
| 0.2% | 0.5% | 1.7% | 0.1% | 0.8% | 0.3% | 0.3% | 0.1% | 0.0% | 0.0% | – | – | |
| 1.2% | 2.0% | 5.0% | 3.9% | 1.7% | 1.8% | 15.4% | 7.3% | 8.9% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | |
| 0.1% | 0.1% | 0.1% | 0.1% | 0.0% | 0.0% | – | – | – | – | – | – | |
| 5.1% | 10.3% | 18.9% | 25.9% | 15.9% | 20.2% | 42.7% | 46.0% | 61.1% | 70.0% | 47.3% | 56.2% | |
| 2.6% | 5.5% | 10.2% | 16.0% | 7.4% | 9.4% | 10.4% | 13.2% | 12.3% | 24.8% | 23.2% | 28.8% | |
| 0.0% | 0.0% | 0.0% | 3.7% | 0.0% | 0.7% | 2.4% | 3.0% | 2.3% | 1.2% | 2.7% | 3.9% | |
| 1.1% | 0.9% | 0.5% | 1.0% | 0.1% | 0.4% | 0.2% | 0.1% | 0.2% | 1.1% | 0.0% | 0.3% | |
| 3.0% | 4.4% | 8.2% | 8.3% | 8.5% | 9.6% | 13.4% | 16.5% | 2.3% | 2.8% | – | – | |
| 94.9% | 89.7% | 81.1% | 74.1% | 84.1% | 80.3% | 57.8% | 54.3% | 39.1% | 30.0% | 52.7% | 43.8% | |
| -13.7% | -36.6% | -115.5% | -224.8% | -141.0% | -180.2% | -261.1% | -151.6% | -221.3% | -290.7% | -254.3% | -414.6% | |
| 15.9% | 21.5% | 33.8% | 39.8% | 30.9% | 31.1% | 41.4% | 26.9% | 39.2% | 53.2% | 47.0% | 79.5% |
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.